


CLAIMS

1. A compound of Formula I



wherein:

R¹ is hydrogen, C₁₋₆alkyl, or C₃₋₇cycloalkyl;

R² is tetrahydroisoquinolyl and is substituted with 1 R⁶ substituent and also with 0-3 halo or C₁₋₆alkyl substituents;

R³ is piperidyl substituted with 0-3 substituents selected from cyano, halo, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, and C₁₋₆haloalkoxy;


R⁴ is C₁₋₆alkyl or C₁₋₆haloalkyl;

R⁵ is C₁₋₆alkyl;

R⁶ is (Ar¹)C₁₋₆alkyl; and

Ar¹ is phenyl substituted with 0-5 substituents selected from cyano, halo, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆haloalkyl, hydroxy, C₁₋₆alkoxy, C₁₋₆haloalkoxy, (hydroxy)C₁₋₆alkoxy, (C₁₋₆alkoxy)C₁₋₆alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanoC₃₋₇cycloalkyl; or a pharmaceutically acceptable salt thereof.

2. A compound or salt according to Claim 1 wherein said compound or salt is



or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound or salt according to Claim 1 or 2.

4. The composition of Claim 3 further comprising at least one other agent for use in treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.
5. The composition of Claim 4 wherein the other agent is dolutegravir.
6. Use of a compound according to Claim 1 or 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating HIV infection, wherein a patient in need thereof is to be administered with said compound or pharmaceutically acceptable salt thereof.
7. The use of Claim 6, wherein the patient is to be further administered with at least one other agent for use in treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.
8. The use of Claim 7 wherein the other agent is dolutegravir.